BlackRock
TNGX icon

BlackRock’s Tango Therapeutics TNGX Stock Holding History

BlackRock’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$389M Buy
12,438,444
+3,690,399
+42% +$91.2M 0.01% 1387
2026
Q1 		$183M Buy
8,748,045
+207,248
+2% +$2.88M ﹤0.01% 1727
2025
Q4 		$75.7M Buy
8,540,797
+2,893,878
+51% +$24.9M ﹤0.01% 2273
2025
Q3 		$47.4M Buy
5,646,919
+183,653
+3% +$1.24M ﹤0.01% 2539
2025
Q2 		$28M Buy
5,463,266
+1,431,254
+35% +$3.54M ﹤0.01% 2818
2025
Q1 		$5.52M Sell
4,032,012
-346,491
-8% -$851K ﹤0.01% 3607
2024
Q4 		$13.5M Buy
4,378,503
+17,168
+0.4% +$79.7K ﹤0.01% 3263
2024
Q3 		$33.6M Buy
4,361,335
+373,483
+9% +$3.56M ﹤0.01% 2709
2024
Q2 		$34.2M Buy
3,987,852
+126,490
+3% +$977K ﹤0.01% 2655
2024
Q1 		$30.7M Sell
3,861,362
-87,914
-2% -$942K ﹤0.01% 2741
2023
Q4 		$39.1M Buy
3,949,276
+391,757
+11% +$3.4M ﹤0.01% 2631
2023
Q3 		$40.1M Sell
3,557,519
-64,957
-2% -$396K ﹤0.01% 2529
2023
Q2 		$12M Buy
3,622,476
+83,564
+2% +$301K ﹤0.01% 3331
2023
Q1 		$14M Sell
3,538,912
-12,259
-0.3% -$71.1K ﹤0.01% 3147
2022
Q4 		$25.7M Buy
3,551,171
+630,761
+22% +$4.44M ﹤0.01% 2893
2022
Q3 		$10.6M Sell
2,920,410
-239,977
-8% -$1.02M ﹤0.01% 3401
2022
Q2 		$14.3M Buy
3,160,387
+1,667,201
+112% +$10.1M ﹤0.01% 3292
2022
Q1 		$11.3M Buy
1,493,186
+340,746
+30% +$2.95M ﹤0.01% 3509
2021
Q4 		$12.6M Sell
1,152,440
-240,728
-17% -$2.89M ﹤0.01% 3530
2021
Q3 		$18M Buy
1,393,168
+793,168
+132% +$9.51M ﹤0.01% 3359
2021
Q2 		$6.83M Hold
600,000
– – ﹤0.01% 3785
2021
Q1 		$6.67M Hold
600,000
– – ﹤0.01% 3805
2020
Q4 		$6.86M Hold
600,000
– – ﹤0.01% 3560
2020
Q3 		$6.22M Buy
+600,000
New +$6.13M ﹤0.01% 3477

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock's TNGX Position: Q2 2026 in Review

BlackRock increased its Tango Therapeutics (TNGX) stake by 42% in Q2 2026, buying an estimated $91.2M and bringing the position to 12,438,444 shares worth $389M. The position accounts for 0.01% of the portfolio, ranked #1387.

BlackRock first reported a position in TNGX in Q3 2020 and has held it in 24 quarters since. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • BlackRock held 12,438,444 shares of Tango Therapeutics worth $389M as of Q2 2026.
  • BlackRock bought 3,690,399 Tango Therapeutics shares in Q2 2026, an estimated $91.2M.
  • Tango Therapeutics made up 0.01% of BlackRock's portfolio in Q2 2026, its #1387 holding.
  • BlackRock first reported a position in Tango Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.